Developer docs
API playgroundTry for free, no card

Search company profiles

Atomic AI

Full company profile

uuid0000gwb

Namestring
Atomic AI
Legal namestring
Atomic AI
Websiteurl
atomic.ai
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Atomic AI is a privately held biotechnology company founded in 2021 and headquartered in San Francisco, California. The company builds AI-driven tools to predict the three-dimensional structure of RNA molecules and to design RNA-targeted small molecules and RNA-based therapeutics, including mRNA vaccines, siRNAs, and circular RNA. Atomic AI's core offering is the PARSE (Platform for AI-driven RNA Structure Exploration) platform, which integrates deep learning foundation models with purpose-built in-house wet-lab assays in a synergistic cycle. The platform is powered by ATOM-1, a proprietary foundation model that the company describes as the first large language model to leverage chemical mapping data for RNA therapeutic optimization. The underlying research originated at Stanford University, with the ARES algorithm published on the cover of Science in August 2021, providing scientific provenance for the company's technology.

Atomic AI generates revenue through a B2B partnership and platform licensing model directed at pharmaceutical and biotechnology companies. The company does not sell products to end customers; instead, it engages potential partners through business development outreach (inquiries routed to bd@atomic.ai) and develops RNA-targeted medicines in therapeutic areas aligned with each partner's strategic focus. Revenue mechanics are consistent with typical biotech platform deals: upfront payments, milestone payments, and potential royalties on successfully developed drug candidates. The company serves a single primary segment — pharmaceutical and biotechnology business units seeking to access previously undruggable RNA targets — and has no publicly disclosed named customers, contracts, or revenue figures.

The company has raised approximately $42 million across funding rounds: a $7 million seed round in 2021 led by 8VC, a $35 million Series A in January 2023 led by Playground Global with participation from 8VC, Greylock, AME Cloud Ventures, Factory, and Not Boring, and an additional undisclosed amount from Modi Ventures in August 2023. Atomic AI has approximately 16 named team members spanning machine learning, RNA biology, cheminformatics, and business operations. Leadership includes founder and CEO Raphael Townshend (Stanford PhD), Chief Scientific Officer Dr. Manjunath Ramarao (former Bristol Myers Squibb), and Head of ML Stephan Eismann. The company has been recognized by Forbes 30 Under 30 (December 2022, founder), Nature Biotechnology Editor's Pick (August 2024), and Pharma's Almanac Five Small Biotechs to Watch (February 2025).

Short descriptiontext

Atomic AI is a San Francisco-based biotech company that combines deep learning foundation models with proprietary wet-lab assays to predict RNA 3D structure and discover RNA-targeted small molecules and RNA-based therapeutics for pharmaceutical and biotechnology partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA drug discovery, machine learning biology, structural biology AI, RNA-targeted therapeutics, foundation models biotech
Industry3 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
AI-driven RNA drug discovery platform
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Platform Licensing and Partnership Agreements
TypeLicensing Royalties
Description

Atomic AI licenses its platform technology to pharmaceutical and biotech partners, enabling them to develop RNA-targeted small molecules in areas of strategic focus. Revenue likely comes through upfront payments, milestone payments, and potential royalties on successful drug development.

atomic.ai
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1ATOM-1
Description

First-of-its-kind large language model that leverages chemical mapping data to streamline RNA therapeutic optimization. Enables precise predictions of RNA structural and functional properties.

atomic.ai
+1 more record
Core offering1 text field

Atomic AI combines machine learning with structural biology to design RNA-targeted small molecules and RNA-based therapeutics. Its proprietary PARSE platform integrates deep learning foundation models with purpose-built in-house wet-lab assays in a synergistic discovery cycle, anchored by the ATOM-1 foundation model that predicts RNA 3D structure and the properties of small molecules, mRNA vaccines, siRNAs, and circular RNA. The platform is offered to pharmaceutical and biotechnology partners to access historically undruggable RNA targets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • First foundation model using chemical mapping data for RNA therapeutic development
+1 more record
Product overview1 text field

Atomic AI offers a unified platform approach combining the PARSE (Platform for AI-driven RNA Structure Exploration) as the core R&D system with ATOM-1 as its foundational AI model. PARSE integrates deep learning foundation models with purpose-built in-house wet-lab assays in a virtuous cycle, while ATOM-1 serves as the large language model enabling precise 3D RNA structure predictions. Together, these products enable the discovery and development of RNA-targeted small molecules and RNA-based therapeutics for treating traditionally undruggable diseases.

Product and service2 records
1PARSE (Platform for AI-driven RNA Structure Exploration)
CategoryAI-driven RNA drug discovery platform
Description

Proprietary R&D platform that integrates cutting-edge deep learning foundation models with purpose-built in-house wet-lab assays in a synergistic cycle for discovering and developing RNA-targeted and RNA-based small molecules; offered to pharmaceutical and biotechnology partners for drug discovery.

2ATOM-1 Foundation Model
CategoryAI foundation model for RNA therapeutics
Description

First-of-its-kind large language model that leverages chemical mapping data to predict RNA structural and functional properties, as well as key characteristics of RNA-based modalities including small molecules, mRNA vaccines, siRNAs, and circular RNA; underpins Atomic AI's PARSE platform.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Frontier AI research company building foundation models for biology (ESM series) and pursuing applications in therapeutics. Comparable as a foundation-model-for-biology company with overlapping talent pool and methodology.

TypeBroad incumbent
Description

AI-driven drug discovery company combining ML with induced pluripotent stem cell biology, with major partnerships (e.g., Bristol Myers Squibb, Eli Lilly). Comparable business model of AI platform + pharma partnerships in a larger, better-funded form.

TypeBroad incumbent
Description

AI biotech platform with pharma partnerships applying ML to drug discovery and clinical development. Comparable as a larger, established AI-for-drug-discovery platform competing for similar pharma AI partnerships.

4Isomorphic Labs
TypeDirect peer
Description

Alphabet/DeepMind spinout applying AlphaFold-style AI to drug discovery, including partnerships with Novartis and Eli Lilly. Directly comparable as a well-capitalized AI-native drug discovery platform with pharma partnership model.

TypeEmerging player
Description

AI protein design company using large language models for novel protein engineering. Comparable as an AI foundation-model-for-biology startup with adjacent (protein, not RNA) focus and similar go-to-market.

TypeBroad incumbent
Description

Public, large-scale AI drug discovery company combining high-throughput wet-lab biology with ML. Comparable as a much larger, well-funded AI-biotech platform pursuing pharma partnerships and internal pipeline development.

TypeDirect peer
Description

AI platform company focused on RNA-targeted medicines and genetic drug discovery. Most directly comparable to Atomic AI given its emphasis on AI-designed RNA-targeted therapeutics.

TypeDirect peer
Description

AI-first RNA biology company (founded by Patrick Collison) focused on designing RNA-based medicines with deep learning. Closely mirrors Atomic AI's mission of using AI to unlock RNA therapeutics.

TypeEmerging player
Description

AI platform for protein engineering and biologics design with pharma partnership model. Comparable as an AI-native biologics platform competing for similar pharma partnership budgets.

TypeDirect peer
Description

Flagship Pioneering-backed AI generative biology company developing RNA- and protein-based programmable medicines using foundation models. Most directly comparable to Atomic AI in applying generative AI to RNA/biological drug design.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Atomic AI

AI-driven RNA drug discovery platformatomic.ai

Atomic AI is a San Francisco-based biotech company that combines deep learning foundation models with proprietary wet-lab assays to predict RNA 3D structure and discover RNA-targeted small molecules and RNA-based therapeutics for pharmaceutical and biotechnology partners.

What Atomic AI does

Atomic AI is a privately held biotechnology company founded in 2021 and headquartered in San Francisco, California. The company builds AI-driven tools to predict the three-dimensional structure of RNA molecules and to design RNA-targeted small molecules and RNA-based therapeutics, including mRNA vaccines, siRNAs, and circular RNA. Atomic AI's core offering is the PARSE (Platform for AI-driven RNA Structure Exploration) platform, which integrates deep learning foundation models with purpose-built in-house wet-lab assays in a synergistic cycle. The platform is powered by ATOM-1, a proprietary foundation model that the company describes as the first large language model to leverage chemical mapping data for RNA therapeutic optimization. The underlying research originated at Stanford University, with the ARES algorithm published on the cover of Science in August 2021, providing scientific provenance for the company's technology.

Atomic AI generates revenue through a B2B partnership and platform licensing model directed at pharmaceutical and biotechnology companies. The company does not sell products to end customers; instead, it engages potential partners through business development outreach (inquiries routed to bd@atomic.ai) and develops RNA-targeted medicines in therapeutic areas aligned with each partner's strategic focus. Revenue mechanics are consistent with typical biotech platform deals: upfront payments, milestone payments, and potential royalties on successfully developed drug candidates. The company serves a single primary segment — pharmaceutical and biotechnology business units seeking to access previously undruggable RNA targets — and has no publicly disclosed named customers, contracts, or revenue figures.

The company has raised approximately $42 million across funding rounds: a $7 million seed round in 2021 led by 8VC, a $35 million Series A in January 2023 led by Playground Global with participation from 8VC, Greylock, AME Cloud Ventures, Factory, and Not Boring, and an additional undisclosed amount from Modi Ventures in August 2023. Atomic AI has approximately 16 named team members spanning machine learning, RNA biology, cheminformatics, and business operations. Leadership includes founder and CEO Raphael Townshend (Stanford PhD), Chief Scientific Officer Dr. Manjunath Ramarao (former Bristol Myers Squibb), and Head of ML Stephan Eismann. The company has been recognized by Forbes 30 Under 30 (December 2022, founder), Nature Biotechnology Editor's Pick (August 2024), and Pharma's Almanac Five Small Biotechs to Watch (February 2025).

Atomic AI firmographics

Firmographics
Name
Atomic AI
Legal name
Atomic AI
Website
https://atomic.ai
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Atomic AI is a San Francisco-based biotech company that combines deep learning foundation models with proprietary wet-lab assays to predict RNA 3D structure and discover RNA-targeted small molecules and RNA-based therapeutics for pharmaceutical and biotechnology partners.
Ownership category
akta.pro rank

Atomic AI industry classification

Industry
Product category
AI-driven RNA drug discovery platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • RNA drug discovery
  • Machine learning biology
  • Structural biology AI
  • RNA-targeted therapeutics
  • Foundation models biotech

Where Atomic AI is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Atomic AI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Platform Licensing and Partnership Agreements: Atomic AI licenses its platform technology to pharmaceutical and biotech partners, enabling them to develop RNA-targeted small molecules in areas of strategic focus. Revenue likely comes through upfront payments, milestone payments, and potential royalties on successful drug development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Atomic AI product offering

Product offering

Core offering

Atomic AI combines machine learning with structural biology to design RNA-targeted small molecules and RNA-based therapeutics. Its proprietary PARSE platform integrates deep learning foundation models with purpose-built in-house wet-lab assays in a synergistic discovery cycle, anchored by the ATOM-1 foundation model that predicts RNA 3D structure and the properties of small molecules, mRNA vaccines, siRNAs, and circular RNA. The platform is offered to pharmaceutical and biotechnology partners to access historically undruggable RNA targets.

Product overview

Atomic AI offers a unified platform approach combining the PARSE (Platform for AI-driven RNA Structure Exploration) as the core R&D system with ATOM-1 as its foundational AI model. PARSE integrates deep learning foundation models with purpose-built in-house wet-lab assays in a virtuous cycle, while ATOM-1 serves as the large language model enabling precise 3D RNA structure predictions. Together, these products enable the discovery and development of RNA-targeted small molecules and RNA-based therapeutics for treating traditionally undruggable diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • ATOM-1: First-of-its-kind large language model that leverages chemical mapping data to streamline RNA therapeutic optimization. Enables precise predictions of RNA structural and functional properties.
  • PARSE (Platform for AI-driven RNA Structure Exploration)

Products and services

  • PARSE (Platform for AI-driven RNA Structure Exploration) Proprietary R&D platform that integrates cutting-edge deep learning foundation models with purpose-built in-house wet-lab assays in a synergistic cycle for discovering and developing RNA-targeted and RNA-based small molecules; offered to pharmaceutical and biotechnology partners for drug discovery.
  • ATOM-1 Foundation Model First-of-its-kind large language model that leverages chemical mapping data to predict RNA structural and functional properties, as well as key characteristics of RNA-based modalities including small molecules, mRNA vaccines, siRNAs, and circular RNA; underpins Atomic AI's PARSE platform.

Quantifiable outcome

  • First foundation model using chemical mapping data for RNA therapeutic development
  • +1 more outcomes

Companies that use Atomic AI

Customer profile

Segments1 record

Ideal customer profiles1 record

Atomic AI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature3 records

Atomic AI partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Atomic AI competitors and assessment

Company assessment

Emerging players

  • EvolutionaryScale: Frontier AI research company building foundation models for biology (ESM series) and pursuing applications in therapeutics. Comparable as a foundation-model-for-biology company with overlapping talent pool and methodology.
  • Profluent Bio: AI protein design company using large language models for novel protein engineering. Comparable as an AI foundation-model-for-biology startup with adjacent (protein, not RNA) focus and similar go-to-market.
  • Cradle Bio: AI platform for protein engineering and biologics design with pharma partnership model. Comparable as an AI-native biologics platform competing for similar pharma partnership budgets.

Broad incumbents

  • Insitro: AI-driven drug discovery company combining ML with induced pluripotent stem cell biology, with major partnerships (e.g., Bristol Myers Squibb, Eli Lilly). Comparable business model of AI platform + pharma partnerships in a larger, better-funded form.
  • Owkin: AI biotech platform with pharma partnerships applying ML to drug discovery and clinical development. Comparable as a larger, established AI-for-drug-discovery platform competing for similar pharma AI partnerships.
  • Recursion Pharmaceuticals: Public, large-scale AI drug discovery company combining high-throughput wet-lab biology with ML. Comparable as a much larger, well-funded AI-biotech platform pursuing pharma partnerships and internal pipeline development.

Direct peers

  • Isomorphic Labs: Alphabet/DeepMind spinout applying AlphaFold-style AI to drug discovery, including partnerships with Novartis and Eli Lilly. Directly comparable as a well-capitalized AI-native drug discovery platform with pharma partnership model.
  • Deep Genomics: AI platform company focused on RNA-targeted medicines and genetic drug discovery. Most directly comparable to Atomic AI given its emphasis on AI-designed RNA-targeted therapeutics.
  • Inceptive: AI-first RNA biology company (founded by Patrick Collison) focused on designing RNA-based medicines with deep learning. Closely mirrors Atomic AI's mission of using AI to unlock RNA therapeutics.
  • Generate Biomedicines: Flagship Pioneering-backed AI generative biology company developing RNA- and protein-based programmable medicines using foundation models. Most directly comparable to Atomic AI in applying generative AI to RNA/biological drug design.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Atomic AI social profiles

Digital presence

Atomic AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Atomic AI leadership team

Management profile

Number of profiles

Profiles5 records

Atomic AI funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Atomic AI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atomic AI

What does Atomic AI do?

Atomic AI combines machine learning with structural biology to design RNA-targeted small molecules and RNA-based therapeutics. Its proprietary PARSE platform integrates deep learning foundation models with purpose-built in-house wet-lab assays in a synergistic discovery cycle, anchored by the ATOM-1 foundation model that predicts RNA 3D structure and the properties of small molecules, mRNA vaccines, siRNAs, and circular RNA. The platform is offered to pharmaceutical and biotechnology partners to access historically undruggable RNA targets.

Is Atomic AI a public or private company?

Atomic AI is a private company. It is classified as venture growth investor backed and is currently operating.

When was Atomic AI founded?

Atomic AI was founded in 2021. It employs 11 to 50 people.

Where is Atomic AI based?

Atomic AI is headquartered in San Francisco, United States, in the North America region.

How does Atomic AI make money?

One revenue line is on record: platform Licensing and Partnership Agreements.

Who are Atomic AI's main competitors?

Emerging players on record are EvolutionaryScale, Profluent Bio and Cradle Bio. Broad incumbents are Insitro, Owkin and Recursion Pharmaceuticals. Direct peers are Isomorphic Labs, Deep Genomics, Inceptive and Generate Biomedicines.

Does Atomic AI have an API?

No public API is recorded for Atomic AI.

What industry is Atomic AI in?

Atomic AI's product category is AI-driven RNA drug discovery platform. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioPharmaTrend17 Companies Pioneering AI Foundation Models in Pharma and BiotechA Business Intelligence article profiles 17 biotech and pharma companies building domain-specific AI foundation models for drug discovery, RNA, protein, pathology, and EEG analysis. Examples include Atomic AI, BioMap, Chai Discovery, Bioptimus, InSilico Medicine, Recursion, Retro Biosciences, Paige, and Piramidal. Funding ranges from seed rounds to $100 million Series A rounds, with BioMap's xTrimo at ~210 billion parameters and Chai-1 outperforming AlphaFold3 on benchmarks.outsourcing-pharma.comAtomic launches to apply AI to small molecule drug discoveryAtomic AI raised $35M in a Series A led by Playground Global, adding to $7M in prior funding. The biotech's AI platform uses 3D RNA structure data to discover RNA drug targets, aiming to overcome barriers in small-molecule drug discovery.WebrazziBiyoteknoloji şirketi Atomic AI, Playground Global liderliğinde 35 milyon dolar yatırım aldıBiyoteknoloji şirketi Atomic AI, Playground Global liderliğinde 35 milyon dolarlık A Serisi yatırım turu tamamladı. Bu yatırımla şirketin toplam finansmanı 42 milyon dolara yükselirken, yapay zeka kullanarak RNA tabanlı ilaç keşfine odaklanıyor.STATBay Area biotech uses AI to unlock RNA structures — and find new therapies in the processAtomic AI, a Bay Area biotech, uses AI to predict RNA structures for drug discovery. The company raised $35 million in a Series A round led by Playground Global. CEO Raphael Townshend aims to help biotechs design RNA therapeutics.TechCrunchWith new funding, Atomic AI envisions RNA as the next frontier in drug discoveryAtomic AI raised $35 million in a Series A led by Playground Global to develop AI tools for RNA structure prediction. The company's model, trained on 18 RNA structures, outperformed others and is being used to target cancers and neurodegenerative diseases.Business Wire BlogAtomic AI Launches with $35 Million Series A Financing to Advance AI-driven RNA Structure Platform for Treating Undruggable DiseasesAtomic AI launched with a $35 million Series A round led by Playground Global, bringing total funding to $42 million. The company's AI-driven RNA structure platform aims to design RNA-targeting small molecules and medicines for undruggable diseases.Venture Capital Access OnlineAtomic AI Launches with $35 Million Series A Financing to Advance AI-driven RNA Structure Platform for Treating Undruggable DiseasesAtomic AI launched today with a $35 million Series A financing round led by Playground Global, involving participation from investors such as 8VC and Greylock. The company utilizes an AI-driven platform to predict 3D RNA structures for the discovery of small molecules and medicines targeting undruggable diseases. This funding supports the advancement of their proprietary technology which integrates machine learning with experimental biology.Silicon Valley JournalsAtomic AI Launches with $35 Million Series A FinancingAtomic AI launched with a $35 million Series A financing round led by Playground Global, with participation from investors including 8VC, Factory HQ, and Greylock. The biotechnology company utilizes machine learning and structural biology to accelerate RNA drug discovery by accurately predicting 3D RNA structures.